Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months

NCT00102791 is registered in ClinicalTrials.gov with Icagen as lead sponsor.

NCT NCT00102791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months
Lead sponsor
Icagen
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2005
Completion date
June 30, 2007
Enrollment
297 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease